Which strategy is most associated with reducing restenosis rates after stent placement?

Which strategy is most associated with reducing restenosis rates after stent placement?

• A. Drug-eluting stents
• B. Long-term anticoagulation
• C. Bypass surgery
• D. Aggressive lipid lowering alone

Answer: (A)

Restenosis after stent placement is mainly driven by neointimal hyperplasia, where smooth muscle cells proliferate inside the stented segment. Drug-eluting stents release antiproliferative medications that locally inhibit this cell growth, substantially reducing neointimal formation and the need for repeat revascularization. Long-term anticoagulation lowers thrombotic risk but doesn’t suppress neointimal hyperplasia, so it doesn’t meaningfully reduce restenosis. Bypass surgery revascularizes a different route and doesn’t address restenosis within a stented artery. Aggressive lipid lowering improves long-term atherosclerotic risk but doesn’t directly prevent restenosis in the stented segment. Therefore, drug-eluting stents are the strategy most associated with reducing restenosis rates after stent placement.

Restenosis after stent placement is mainly driven by neointimal hyperplasia, where smooth muscle cells proliferate inside the stented segment. Drug-eluting stents release antiproliferative medications that locally inhibit this cell growth, substantially reducing neointimal formation and the need for repeat revascularization. Long-term anticoagulation lowers thrombotic risk but doesn’t suppress neointimal hyperplasia, so it doesn’t meaningfully reduce restenosis. Bypass surgery revascularizes a different route and doesn’t address restenosis within a stented artery. Aggressive lipid lowering improves long-term atherosclerotic risk but doesn’t directly prevent restenosis in the stented segment. Therefore, drug-eluting stents are the strategy most associated with reducing restenosis rates after stent placement.